{"id":5730,"date":"2021-03-22T13:43:22","date_gmt":"2021-03-22T13:43:22","guid":{"rendered":"https:\/\/www.theisn.org\/wcn\/?page_id=5730"},"modified":"2021-03-25T16:47:31","modified_gmt":"2021-03-25T16:47:31","slug":"industry-program","status":"publish","type":"page","link":"https:\/\/bk.theisn.org\/wcn21\/exhibition-industry\/industry-program\/","title":{"rendered":"Industry Program"},"content":{"rendered":"

[vc_row][vc_column][vc_column_text]<\/p>\n

Industry Program<\/strong><\/h3>\n

Industry symposium sessions will offer pertinent data on the latest scientific information and developments from the industry. Hear from leading experts <\/strong>on the latest advances in nephrology practices, therapies, services, and technologies. There are up to five<\/strong> industry sessions per day included in your WCN registration. Industry symposia are also open-access!<\/p>\n

The program will run daily between April 16-19, 2021 from 08:00-14:00 Eastern Daylight Time to reach viewers in North & South America. For European and African participants, the program can be viewed between 14:00-20:00 Central European Time. For time zones without convenient access to the live program (Asian and Australian participants) sessions will be available for on-demand viewing.<\/p>\n

Detailed programs will be available here in February.[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column width=”1\/4″][vc_column_text]<\/p>\n

Friday, April 16<\/strong><\/h4>\n

11:00 – 12:00 EDT<\/strong><\/p>\n

[\/vc_column_text][\/vc_column][vc_column width=”1\/4″][vc_column_text]<\/p>\n

Saturday, April 17<\/strong><\/h4>\n

11:00 – 12:00 EDT<\/strong><\/p>\n

[\/vc_column_text][\/vc_column][vc_column width=”1\/4″][vc_column_text]<\/p>\n

Sunday, April 18<\/strong><\/h4>\n

11:00 – 12:00 EDT<\/strong><\/p>\n

[\/vc_column_text][\/vc_column][vc_column width=”1\/4″][vc_column_text]<\/p>\n

Monday, April 19<\/strong><\/h4>\n

08:00 – 09:00 EDT<\/strong><\/p>\n

[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column width=”1\/4″][vc_column_text]<\/p>\n

\"\"<\/p>\n

[\/vc_column_text][\/vc_column][vc_column width=”1\/4″][vc_column_text]<\/p>\n

\"\"<\/p>\n

[\/vc_column_text][\/vc_column][vc_column width=”1\/4″][vc_column_text]\"\"[\/vc_column_text][\/vc_column][vc_column width=”1\/4″][vc_column_text]\"\"[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column width=”1\/4″][vc_column_text]<\/p>\n

\"\"<\/p>\n

[\/vc_column_text][\/vc_column][vc_column width=”1\/4″][vc_column_text]\"\"[\/vc_column_text][\/vc_column][vc_column width=”1\/4″][vc_column_text]\"\"[\/vc_column_text][\/vc_column][vc_column width=”1\/4″][vc_column_text]<\/p>\n

\"\"<\/h5>\n

[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column width=”1\/4″][vc_column_text]\"\"[\/vc_column_text][\/vc_column][vc_column width=”1\/4″][vc_column_text]<\/p>\n

\"\"<\/h3>\n

[\/vc_column_text][\/vc_column][vc_column width=”1\/4″][vc_column_text]<\/p>\n

<\/h5>\n
Slot available<\/h5>\n

[\/vc_column_text][\/vc_column][vc_column width=”1\/4″][vc_column_text]<\/p>\n

<\/h5>\n
Slot available<\/h5>\n

[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column width=”1\/4″][vc_column_text]\"\"[\/vc_column_text][\/vc_column][vc_column width=”1\/4″][vc_column_text]<\/p>\n

\"\"<\/h3>\n

[\/vc_column_text][\/vc_column][vc_column width=”1\/4″][vc_column_text]<\/p>\n

<\/h5>\n
Slot available<\/h5>\n

[\/vc_column_text][\/vc_column][vc_column width=”1\/4″][vc_column_text]<\/p>\n

<\/h5>\n
Slot available<\/h5>\n

[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column width=”1\/4″][vc_column_text]<\/p>\n

<\/h5>\n
Slot available<\/h5>\n

[\/vc_column_text][\/vc_column][vc_column width=”1\/4″][vc_column_text]<\/p>\n

<\/h5>\n
Slot available<\/h5>\n

[\/vc_column_text][\/vc_column][vc_column width=”1\/4″][vc_column_text]<\/p>\n

<\/h5>\n
Slot available<\/h5>\n

[\/vc_column_text][\/vc_column][vc_column width=”1\/4″][vc_column_text]<\/p>\n

<\/h5>\n
Slot available<\/h5>\n

[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_separator color=”pink”][vc_column_text]<\/p>\n

<\/h5>\n
Last updated: February 26, 2021<\/h5>\n

[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_tta_accordion c_position=”right” active_section=”1″ collapsible_all=”true” el_class=”accordion-isn”][vc_tta_section title=”Industry Symposia Program (Friday, April 16, 2021)” tab_id=”industry-symposia-program-16″][vc_column_text]\"\"<\/p>\n

    \n
  • Contemporary concepts in ADPKD: Innovations in clinical practice and novel disease mechanisms <\/strong><\/li>\n
  • Organizer: <\/strong>\u00a0Genzyme<\/li>\n
  • Room: <\/strong>Room 5<\/li>\n
  • Time: <\/strong>11:00 \u2013 12:00<\/li>\n
  • Chair(s):<\/strong>Merlis, Ronli (United States)<\/li>\n
  • Schedule: <\/strong>
    \n\n\n\n\n\n\n\n\n
    Time<\/strong><\/td>\nTitle<\/strong><\/td>\nSpeaker<\/strong><\/td>\n<\/tr>\n
    11:00 – 11:02<\/td>\nWelcome and Introduction<\/td>\nLanktree, Matthew (Canada)<\/td>\n<\/tr>\n
    11:02 – 11:10<\/td>\nInsights into ADPKD from genetic studies<\/td>\nLanktree, Matthew (Canada)<\/td>\n<\/tr>\n
    11:10 – 11:35<\/td>\nClinical practice update and case presentations in ADPKD<\/td>\nPei, York (Canada)<\/td>\n<\/tr>\n
    11:35 – 11:50<\/td>\nNovel disease mechanisms in ADPKD<\/td>\nMaski, Manish (United States)<\/td>\n<\/tr>\n
    11:50 – 12:00<\/td>\nQ&A<\/td>\nAll Faculty (Canada)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/li>\n<\/ul>\n

    [\/vc_column_text][vc_column_text]\"\"<\/p>\n

      \n
    • Why Target the Mucosal Immune System of the Gut to Treat IgA Nephropathy?<\/strong><\/li>\n
    • Organizer: <\/strong>Callitidas
      \n<\/strong><\/li>\n
    • Room: <\/strong>Room 2<\/li>\n
    • Time: <\/strong>11:00 \u2013 12:00<\/li>\n
    • Chair(s): <\/strong>Udell, Andrew (Sweden)<\/li>\n
    • Schedule: <\/strong>
      \n\n\n\n\n\n\n\n\n
      <\/td>\nTitle<\/strong><\/td>\nSpeaker<\/strong><\/td>\n<\/tr>\n
      <\/td>\nWelcome and introductions<\/td>\nBARRATT, Jonathan<\/td>\n<\/tr>\n
      <\/td>\nTargets for new drug development in IgAN<\/td>\nRovin, Brad<\/td>\n<\/tr>\n
      <\/td>\nThe rationale for targeting the mucosal immune system in IgAN<\/td>\nBARRATT, Jonathan<\/td>\n<\/tr>\n
      <\/td>\nClinical experience of targeting the Peyer\u2019s patches in IgAN<\/td>\nLafayette, Richard<\/td>\n<\/tr>\n
      <\/td>\nQ&A<\/td>\nBARRATT, Jonathan<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/li>\n<\/ul>\n

      [\/vc_column_text][vc_column_text]\"\"<\/p>\n

        \n
      • Nonsteroidal MRAs: A new chapter for the management of CKD in T2D<\/strong><\/li>\n
      • Organizer: <\/strong>Bayer<\/li>\n
      • Room: <\/strong>Room 3<\/li>\n
      • Time: <\/strong>11:00 \u2013 12:00<\/li>\n
      • Chair(s): <\/strong>Erdmann, Stephanie (Germany)<\/li>\n
      • Schedule: <\/strong>
        \n\n\n\n\n\n\n\n\n
        Time<\/strong><\/td>\nTitle<\/strong><\/td>\nSpeaker<\/strong><\/td>\n<\/tr>\n
        11:00 – 11:05<\/td>\nWelcome and introductions<\/td>\nPecoits-Filho, Roberto<\/td>\n<\/tr>\n
        11:05 – 11:25<\/td>\nInflammation and fibrosis as a driver of CKD progression: An opportunity for intervention?<\/td>\nCherney, David<\/td>\n<\/tr>\n
        11:25 – 11:45<\/td>\nImpact of MR antagonism in CKD in T2D: Lessons from the FIDELIO-DKD trial<\/td>\nBakris, George<\/td>\n<\/tr>\n
        11:45 – 11:55<\/td>\nQ&A<\/td>\nAll Faculty<\/td>\n<\/tr>\n
        11:55 – 12:00<\/td>\nSummary & Close<\/td>\nAll Faculty<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/li>\n<\/ul>\n

        [\/vc_column_text][vc_column_text]\"\"<\/p>\n

          \n
        • Proteinuria Treatment Targets in Glomerular Disease: Providing Insights into Clinical Outcomes<\/strong><\/li>\n
        • Organizer: <\/strong>Travere<\/li>\n
        • Room: <\/strong>Room 1<\/li>\n
        • Time: <\/strong>11:00 \u2013 12:00<\/li>\n
        • Chair(s): <\/strong>Hammer, Bernice (United States)<\/li>\n
        • Schedule: <\/strong>
          \n\n\n\n\n\n\n\n\n
          Time<\/strong><\/td>\nTitle<\/strong><\/td>\nSpeaker<\/strong><\/td>\n<\/tr>\n
          11:00 – 11:30<\/td>\nIntroduction and setting the scene<\/td>\nBarbour, Sean (Canada)<\/td>\n<\/tr>\n
          <\/td>\nProteinuria targets in FSGS<\/td>\nMariani, Laura (United States)<\/td>\n<\/tr>\n
          <\/td>\nProteinuria targets in IgAN<\/td>\nBarbour, Sean (Canada)<\/td>\n<\/tr>\n
          <\/td>\nProteinuria as surrogate endpoint for regulatory approval of novel therapeutics in glomerular disease<\/td>\nCarroll, Kevin J. (United States)<\/td>\n<\/tr>\n
          <\/td>\nClose, Q&A and integrated polling<\/td>\nBarbour, Sean (Canada)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/li>\n<\/ul>\n

          [\/vc_column_text][\/vc_tta_section][vc_tta_section title=”Industry Symposia Program (Saturday, April 17, 2021)” tab_id=”industry-symposia-program-17″][vc_column_text]\"\"<\/p>\n

            \n
          • The Challenge of Slowing Diabetic Kidney Disease Progression And Reducing Cardiovascular Risk: Recent Advances and Novel Strategies<\/strong><\/li>\n
          • Organizer: <\/strong>Cardiometabolic Health Congress<\/li>\n
          • Room: <\/strong>Room 5<\/li>\n
          • Time: <\/strong>11:00 \u2013 12:00<\/li>\n
          • Chair(s): <\/strong>McAdams, Karin (United States)<\/li>\n
          • Schedule: <\/strong>
            \n\n\n\n\n\n\n\n\n
            Time<\/strong><\/td>\nTitle<\/strong><\/td>\nSpeaker<\/strong><\/td>\n<\/tr>\n
            <\/td>\nIntroduction, Background and Future of DKD<\/td>\nBakris, George L. (United States)<\/td>\n<\/tr>\n
            <\/td>\nNew Perspectives in the Management of CKD in T2D: the Eemerging Role of MRAs<\/td>\nAgarwal, Rajiv (United States)<\/td>\n<\/tr>\n
            <\/td>\nEffect of Finerenone on CKD Outcomes in T2D<\/td>\nBakris, George L. (United States)<\/td>\n<\/tr>\n
            <\/td>\nFinerenone and Cardiovascular Outcomes<\/td>\nFilippatos, Gerasimos (Greece)<\/td>\n<\/tr>\n
            <\/td>\nPanel Discussion, Q&A and Closing<\/td>\nAll Faculty<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/li>\n<\/ul>\n

            [\/vc_column_text][vc_column_text]\"\"<\/p>\n

              \n
            • SGLT2 inhibitors: The next step to optimal care in CKD<\/strong><\/li>\n
            • Organizer: <\/strong>AstraZeneca – Change IME<\/li>\n
            • Room: <\/strong>Room 1<\/li>\n
            • Time: <\/strong>11:00 \u2013 12:00<\/li>\n
            • Chair(s): <\/strong>Yu, Alice (United Kingdom)<\/li>\n
            • Schedule: <\/strong>
              \n\n\n\n\n\n\n\n\n
              Time<\/strong><\/td>\nTitle<\/strong><\/td>\nSpeaker<\/strong><\/td>\n<\/tr>\n
              11:00 – 11:30<\/td>\nWelcome and Introduction<\/td>\nTuttle, Katherine (United States)<\/td>\n<\/tr>\n
              <\/td>\nImpacting clinical practice \u2013 SGLT2 inhibitors in CKD<\/td>\nCorrea-Rotter, Ricardo (Mexico)<\/td>\n<\/tr>\n
              <\/td>\nHow SGLT2 inhibitors fit in the CKD management framework<\/td>\nCherney, David (Canada)<\/td>\n<\/tr>\n
              <\/td>\nInitiating SGLT2 inhibitors \u2013 the cardiologist\u2019s experience<\/td>\nJhund, Pardeep (United Kingdom)<\/td>\n<\/tr>\n
              <\/td>\nClose and Q&A<\/td>\nAll Faculty<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/li>\n<\/ul>\n

              [\/vc_column_text][vc_column_text]\"\"<\/p>\n

                \n
              • Kidney itch: what\u2019s new and what to do<\/strong><\/li>\n
              • Organizer: <\/strong>Connect2 CME<\/li>\n
              • Room: <\/strong>Room 4<\/li>\n
              • Time: <\/strong>11:00 \u2013 12:00<\/li>\n
              • Chair(s): <\/strong>Watty-Miller, Mandi (United Kingdom)<\/li>\n
              • Schedule: <\/strong>
                \n\n\n\n\n\n\n\n\n
                <\/td>\nTitle<\/strong><\/td>\nSpeaker<\/strong><\/td>\n<\/tr>\n
                <\/td>\nWelcome and Introduction<\/td>\nRayner, Hugh (United Kingdom)
                \nSukul, Nidhi (United Kingdom)<\/td>\n<\/tr>\n
                <\/td>\nA patient’s experience<\/td>\nRigatto, Claudio (United Kingdom)<\/td>\n<\/tr>\n
                <\/td>\nThe burden and impact of kidney itch worldwide<\/td>\nRayner, Nidhi (United Kingdom)<\/td>\n<\/tr>\n
                <\/td>\nWhy do kidney patients itch?<\/td>\nRigatto, Claudio (United Kingdom)<\/td>\n<\/tr>\n
                <\/td>\nRetrieving data. Wait a few seconds and try to cut or copy again.<\/td>\nRayner, Hugh (United Kingdom)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/li>\n<\/ul>\n

                [\/vc_column_text][vc_column_text]\"\"<\/p>\n

                  \n
                • A discussion with KDIGO: Individual optimization of management of CKD patients with diabetes and CVD comorbidities<\/strong><\/li>\n
                • Organizer: <\/strong>Boheringer\/Lilly-KDIGO<\/li>\n
                • Room: <\/strong>Room 3<\/li>\n
                • Time: <\/strong>11:00 \u2013 12:00<\/li>\n
                • Chair(s): <\/strong>Danielle Green (United States)<\/li>\n
                • Schedule: <\/strong>
                  \n\n\n\n\n\n\n\n\n
                  <\/td>\nTitle<\/strong><\/td>\nSpeaker<\/strong><\/td>\n<\/tr>\n
                  <\/td>\nWelcome and Introductions<\/td>\nWanner, Christoph (Germany)<\/td>\n<\/tr>\n
                  <\/td>\nSGLT2 inhibitors and GLP-1 receptor agonists: Different classes, different modes of kidney protection<\/td>\nLambers Heerspink, Hiddo (The Netherlands)<\/td>\n<\/tr>\n
                  <\/td>\nCase 1: Kidney benefits associated with current pharmacotherapies in patients with CKD and diabetes<\/td>\nRossing, Peter (Demnark)<\/td>\n<\/tr>\n
                  <\/td>\nCase 2: Cardiovascular benefits associated with current pharmacotherapies in patients with CKD and diabetes<\/td>\nMichos, Erin (United States)<\/td>\n<\/tr>\n
                  <\/td>\nPanel discussion<\/td>\nAll Faculty<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/li>\n<\/ul>\n

                  [\/vc_column_text][\/vc_tta_section][vc_tta_section title=”Industry Symposia Program (Sunday, April 18, 2021)” tab_id=”industry-symposia-program-18″][vc_column_text]\"\"<\/p>\n

                    \n
                  • Treating Anemia of CKD: Real-World Clinical Experience with HIP-PH Inhibitors<\/strong><\/li>\n
                  • Organizer: <\/strong>AstraZeneca – Change IME<\/li>\n
                  • Room: <\/strong>Room 1<\/li>\n
                  • Time: <\/strong>11:00 \u2013 12:00<\/li>\n
                  • Chair(s): <\/strong>Yu, Alice (United Kingdom)<\/li>\n
                  • Schedule: <\/strong>
                    \n\n\n\n\n\n\n\n\n
                    Time<\/strong><\/td>\nTitle<\/strong><\/td>\nSpeaker<\/strong><\/td>\n<\/tr>\n
                    <\/td>\nWelcome and Introduction<\/td>\nLevin, Adeera (Canada)
                    \nHao, Chaun-Ming (China)<\/td>\n<\/tr>\n
                    <\/td>\nHIF-PH inhibitors: Evidence from clinical trials<\/td>\nProvenzano, Robert (United States)<\/td>\n<\/tr>\n
                    <\/td>\nMy clinical experience with HIF-PH inhibitors<\/td>\nHao, Chaun-Ming (China)<\/td>\n<\/tr>\n
                    <\/td>\nChairs\u2019 summary and Q&A<\/td>\nLevin, Adeera (Canada)<\/td>\n<\/tr>\n
                    <\/td>\n<\/td>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/li>\n<\/ul>\n

                    [\/vc_column_text][vc_column_text]\"\"<\/p>\n

                      \n
                    • Fabry Disease: An Unexpected Cause of Renal Disease<\/strong><\/li>\n
                    • Organizer: <\/strong>Excel CME<\/li>\n
                    • Room: <\/strong>Room 2<\/li>\n
                    • Time: <\/strong>11:00 \u2013 12:00<\/li>\n
                    • Chair(s):<\/strong> Rebull, Grace (United States)<\/li>\n
                    • Schedule: <\/strong>
                      \n\n\n\n\n\n\n\n\n
                      Time<\/strong><\/td>\nTitle<\/strong><\/td>\nSpeaker<\/strong><\/td>\n<\/tr>\n
                      11:00 – 11:30<\/td>\nOverview of Fabry Disease: Classic vs Non-Classic<\/td>\nMauer, Michael (United States)<\/td>\n<\/tr>\n
                      Renal Manifestations: Biomarkers, Clinical, Kidney Pathology, Evaluation<\/td>\n<\/tr>\n
                      11:30 – 12:00<\/td>\nEvidence-based Long-term Disease Management Therapy<\/td>\nORTIZ, ALBERTO (Spain)<\/td>\n<\/tr>\n
                      Current and Emerging Therapies and Treatment Recommendations<\/td>\n<\/tr>\n
                      12:00 – 12:30<\/td>\nQ&A and Closing<\/td>\nAll Faculty<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/li>\n<\/ul>\n

                      [\/vc_column_text][\/vc_tta_section][vc_tta_section title=”Industry Symposia Program (Monday, April 19, 2021)” tab_id=”industry-symposia-program-18″][vc_column_text]\"\"<\/p>\n

                        \n
                      • Examining Primary Hyperoxaluria Type 1 and Results from ILLUMINATE-A and ILLUMINATE-B Clinical Trials<\/strong><\/li>\n
                      • Organizer: <\/strong>Alnylam<\/li>\n
                      • Room: <\/strong>Room 2<\/li>\n
                      • Time: <\/strong>08:00 \u2013 09:00<\/li>\n
                      • Chair(s): <\/strong>Yu, Alice (United Kingdom)<\/li>\n
                      • Schedule: <\/strong>
                        \n\n\n\n\n\n
                        Time<\/strong><\/td>\nTitle<\/strong><\/td>\nSpeaker<\/strong><\/td>\n<\/tr>\n
                        08:00 \u2013 08:45<\/td>\nExamining Primary Hyperoxaluria Type 1 and Results from ILLUMINATE-A and ILLUMINATE-B Clinical Trials<\/td>\nSaland, Jeffrey (United States)<\/td>\n<\/tr>\n
                        08:45 \u2013 09:00<\/td>\nQuestions and answers<\/td>\nSaland, Jeffrey (United States)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/li>\n<\/ul>\n

                        [\/vc_column_text][vc_column_text]\"\"<\/p>\n

                          \n
                        • New Insights in Alport Syndrome and Genetic Testing<\/strong><\/li>\n
                        • Organizer: <\/strong>Reata<\/li>\n
                        • Room: <\/strong>Room 1<\/li>\n
                        • Time: <\/strong>08:00 \u2013 09:00<\/li>\n
                        • Chair(s):<\/strong> Dolly Livingston (United States)<\/li>\n
                        • Schedule: <\/strong>
                          \n\n\n\n\n\n\n\n\n
                          Time<\/strong><\/td>\nTitle<\/strong><\/td>\nSpeaker<\/strong><\/td>\n<\/tr>\n
                          08:00 – 08:10<\/td>\nHow Alport Syndrome is Diagnosed and Triaged<\/td>\nTorra, Roser (Spain)<\/td>\n<\/tr>\n
                          08:10 – 08:20<\/td>\nClassification\/Disease Subtypes<\/td>\nTorra, Roser (Spain)<\/td>\n<\/tr>\n
                          08:20 – 08:30<\/td>\nGenetics underlying the Disease and Prognosis<\/td>\nKnebelmann, Bertrand (France)<\/td>\n<\/tr>\n
                          08:30 – 08:45<\/td>\nCase Studies in Alport Syndrome<\/td>\nKnebelmann, Bertrand (France)<\/td>\n<\/tr>\n
                          08:45 – 09:00<\/td>\nQuestions and Answers<\/td>\nTorra, Roser – Knebelmann, Bertrand<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/li>\n<\/ul>\n

                          [\/vc_column_text][\/vc_tta_section][\/vc_tta_accordion][\/vc_column][\/vc_row]<\/p>\n","protected":false},"excerpt":{"rendered":"

                          [vc_row][vc_column][vc_column_text] Industry Program Industry symposium sessions will offer pertinent data on the latest scientific information and developments from the industry. Hear from leading experts on the latest advances in nephrology practices, therapies, services, and technologies. There are up to five industry sessions per day included in your WCN registration. Industry symposia are also open-access! The […]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":2724,"menu_order":1,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-5730","page","type-page","status-publish","hentry"],"yoast_head":"\nIndustry Program - World Congress of Nephrology<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/bk.theisn.org\/wcn21\/exhibition-industry\/industry-program\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Industry Program - World Congress of Nephrology\" \/>\n<meta property=\"og:description\" content=\"[vc_row][vc_column][vc_column_text] Industry Program Industry symposium sessions will offer pertinent data on the latest scientific information and developments from the industry. Hear from leading experts on the latest advances in nephrology practices, therapies, services, and technologies. There are up to five industry sessions per day included in your WCN registration. Industry symposia are also open-access! The […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/bk.theisn.org\/wcn21\/exhibition-industry\/industry-program\/\" \/>\n<meta property=\"og:site_name\" content=\"World Congress of Nephrology\" \/>\n<meta property=\"article:modified_time\" content=\"2021-03-25T16:47:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.theisn.org\/wcn\/wp-content\/uploads\/sites\/2\/2020\/11\/Travere-logo-300x66.png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebSite\",\"@id\":\"https:\/\/bk.theisn.org\/wcn21\/#website\",\"url\":\"https:\/\/bk.theisn.org\/wcn21\/\",\"name\":\"World Congress of Nephrology\",\"description\":\"International Society of Nephrology - wcn\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":\"https:\/\/bk.theisn.org\/wcn21\/?s={search_term_string}\",\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"ImageObject\",\"@id\":\"https:\/\/bk.theisn.org\/wcn21\/exhibition-industry\/industry-program\/#primaryimage\",\"inLanguage\":\"en-US\",\"url\":\"https:\/\/www.theisn.org\/wcn\/wp-content\/uploads\/sites\/2\/2020\/11\/Travere-logo-300x66.png\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/bk.theisn.org\/wcn21\/exhibition-industry\/industry-program\/#webpage\",\"url\":\"https:\/\/bk.theisn.org\/wcn21\/exhibition-industry\/industry-program\/\",\"name\":\"Industry Program - World Congress of Nephrology\",\"isPartOf\":{\"@id\":\"https:\/\/bk.theisn.org\/wcn21\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/bk.theisn.org\/wcn21\/exhibition-industry\/industry-program\/#primaryimage\"},\"datePublished\":\"2021-03-22T13:43:22+00:00\",\"dateModified\":\"2021-03-25T16:47:31+00:00\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/bk.theisn.org\/wcn21\/exhibition-industry\/industry-program\/\"]}]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","_links":{"self":[{"href":"https:\/\/bk.theisn.org\/wcn21\/wp-json\/wp\/v2\/pages\/5730","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bk.theisn.org\/wcn21\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/bk.theisn.org\/wcn21\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/bk.theisn.org\/wcn21\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/bk.theisn.org\/wcn21\/wp-json\/wp\/v2\/comments?post=5730"}],"version-history":[{"count":5,"href":"https:\/\/bk.theisn.org\/wcn21\/wp-json\/wp\/v2\/pages\/5730\/revisions"}],"predecessor-version":[{"id":5808,"href":"https:\/\/bk.theisn.org\/wcn21\/wp-json\/wp\/v2\/pages\/5730\/revisions\/5808"}],"up":[{"embeddable":true,"href":"https:\/\/bk.theisn.org\/wcn21\/wp-json\/wp\/v2\/pages\/2724"}],"wp:attachment":[{"href":"https:\/\/bk.theisn.org\/wcn21\/wp-json\/wp\/v2\/media?parent=5730"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}